Research map: Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial

Back to the article

Papers in this map

  1. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study · Arjun Vasant Balar · 2021 · 566 citations · Cited by this paper
  2. Gemcitabine-Based Bladder Preservation in BCG-Unresponsive High-Risk NMIBC: Evidence, Limitations, and Clinical Positioning · Aris Kaltsas · 2026 · Cites this paper
  3. Consensus statements from the first Gynecologic Cancer InterGroup Cervical Cancer Consensus Conference in Clinical Research · 2026 · Related
  4. Advances in diagnosis and treatment of bladder cancer · Antonio López-Beltrán · 2024 · 496 citations · Cited by this paper
  5. Pan-cancer oncolytic virotherapy through disruption of tumor cell mitochondrial dynamics · Shufeng Feng · 2026 · Cites this paper
  6. A step forward for precision oncology in thyroid cancer · 2026 · Related
  7. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial · Stephen Anthony Boorjian · 2020 · 478 citations · Cited by this paper
  8. Reversal of repeated red cards reprieves RP-1 · Richard G. Vile · 2026 · Cites this paper
  9. RCP calls for UK to recognise air pollution as a public health emergency · 2026 · Related
  10. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment · Jeffrey M. Holzbeierlein · 2024 · 420 citations · Cited by this paper
  11. Beyond cold to hot: oncolytic virotherapy as the next cornerstone of immuno-oncology · William W.-G. Jia · 2026 · Cites this paper
  12. French MPs vote for sharp cuts in cadmium content in fertilisers · 2026 · Related
  13. EFFICACY AND SAFETY OF VALRUBICIN FOR THE TREATMENT OF BACILLUS CALMETTE-GUERIN REFRACTORY CARCINOMA IN SITU OF THE BLADDER · Gary D. Steinberg · 2000 · 346 citations · Cited by this paper
  14. Trial design drives outcomes: harmonising efficacy across BCG ‐unresponsive bladder carcinoma in situ trials · Daniele Robesti · 2026 · Cites this paper
  15. The intermediate-risk gap in AI-based breast cancer stratification · 2026 · Related
  16. European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)—A Summary of the 2024 Guidelines Update · Paolo Gontero · 2024 · 304 citations · Cited by this paper
  17. Cretostimogene grenadenorepvec: promise beyond response · Daniele Robesti · 2026 · Cites this paper
  18. Perioperative systemic therapy versus surgery alone for resectable colorectal peritoneal-only metastases (CAIRO6): a randomised, open-label, phase 3 trial · 2026 · Related
  19. An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non–muscle-invasive bladder cancer: Interim results · Vignesh T. Packiam · 2017 · 251 citations · Cited by this paper
  20. Gastric cancer with peritoneal metastases: hype or hope for HIPEC? · 2026 · Related
  21. CG0070, a Conditionally Replicating Granulocyte Macrophage Colony-Stimulating Factor–Armed Oncolytic Adenovirus for the Treatment of Bladder Cancer · Nagarajan Ramesh · 2006 · 244 citations · Cited by this paper
  22. Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS) · 2026 · Related
  23. A First in Human Phase 1 Study of CG0070, a GM-CSF Expressing Oncolytic Adenovirus, for the Treatment of Nonmuscle Invasive Bladder Cancer · James M. Burke · 2012 · 238 citations · Cited by this paper
  24. Development and validation of artificial intelligence-assisted volumetric response criteria in pleural mesothelioma (ARTIMES): a retrospective, multicohort, multicentre study · 2026 · Related
  25. IL-15 Superagonist NAI in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer · Karim Chamie · 2022 · 177 citations · Cited by this paper
  26. Short-term morbidity and mortality following radical cystectomy: a systematic review · Sophia Liff Maibom · 2021 · 171 citations · Cited by this paper
  27. Sequential Intravesical Gemcitabine and Docetaxel for the Salvage Treatment of Non-Muscle Invasive Bladder Cancer · Ryan L. Steinberg · 2015 · 122 citations · Cited by this paper
  28. A Phase 2 Trial of Intravesical Gemcitabine and Docetaxel in the Treatment of Bacillus Calmette-Guérin‒Naïve Nonmuscle-Invasive Urothelial Carcinoma of the Bladder · Sunil Patel · 2024 · 41 citations · Cited by this paper
  29. Identification of Pretreatment Agents to Enhance Adenovirus Infection of Bladder Epithelium · Nagarajan Ramesh · 2004 · 39 citations · Cited by this paper
  30. Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial · Roger Li · 2024 · 35 citations · Cited by this paper
  31. An evaluation of trends in the representation of patients by age, sex, and diverse race/ethnic groups in bladder and kidney cancer clinical trials · Juan Francisco Javier-DesLoges · 2022 · 19 citations · Cited by this paper
  32. Adherence to First-Line Intravesical Bacillus Calmette-Guérin Therapy in the Context of Guideline Recommendations for US Patients With High-Risk Non-muscle Invasive Bladder Cancer · Franklin D. Gaylis · 2024 · 12 citations · Cited by this paper
  33. Radical cystectomy mortality in older patients: a systematic review and meta‐analysis · Jake A. Tempo · 2025 · 9 citations · Cited by this paper
  34. Intravesical Therapy Compared to Radical Cystectomy Among Patients With Non-Muscle Invasive Bladder Cancer Requiring Additional Treatment After Induction BCG · Christopher B. Anderson · 2022 · 5 citations · Cited by this paper
  35. Systematic Review and Meta-Analysis of Response Rates in BCG-unresponsive Non–Muscle-Invasive Bladder Cancer: a Consensus Statement From the International Bladder Cancer Group · Kyle M. Rose · 2022 · 5 citations · Cited by this paper
  36. Integrating gene therapy into the treatment paradigm for non-muscle invasive bladder cancer · Alexis R. Steinmetz · 2025 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)